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Abstract: Alzheimer’s disease (AD) is an age-dependent neurodegenerative disorder and 
the most common cause of dementia. The early stages of AD are characterized by short-term 
memory loss. Once the disease progresses, patients experience difficulties in sense of direction, 
oral communication, calculation, ability to learn, and cognitive thinking. The median duration 
of the disease is 10 years. The pathology is characterized by deposition of amyloid beta pep-
tide (so-called senile plaques) and tau protein in the form of neurofibrillary tangles. Currently, 
two classes of drugs are licensed by the European Medicines Agency for the treatment of AD, 
ie, acetylcholinesterase inhibitors for mild to moderate AD, and memantine, an N-methyl-D-
aspartate receptor antagonist, for moderate and severe AD. Treatment with acetylcholinesterase 
inhibitors or memantine aims at slowing progression and controlling symptoms, whereas drugs 
under development are intended to modify the pathologic steps leading to AD. Herein, we 
review the clinical features, pharmacologic properties, and cost-effectiveness of the available 
acetylcholinesterase inhibitors and memantine, and focus on disease-modifying drugs aiming 
to interfere with the amyloid beta peptide, including vaccination, passive immunization, and 
tau deposition.
Keywords: Alzheimer’s disease, acetylcholinesterase inhibitors, memantine, disease-modifying 
drugs, diagnosis, treatment
Introduction
Alzheimer’s disease (AD) is the most common neurodegenerative disorder and the 
most prevalent cause of dementia with ageing. The prevalence of AD increases with 
age, from 5% of people affected after 65 years of age to about 30% in people aged 
85 years or older.
In the majority of cases, AD develops as a result of multiple factors, with increasing 
age bringing the greatest risk; nevertheless, up to 3%–5% of cases are linked to genetic 
causes. Mutations in genes encoding for amyloid precursor protein (APP), presenilin 1 
(PSEN1), and presenilin 2 (PSEN2) account for about 5% of cases, and are character-
ized by an early onset (before 65 years of age). Comorbidities and lifestyle are also 
contributing factors. In this regard, several studies have been designed to determine the 
role of diet in contributing to the risk of AD. The Washington Heights-Inwood Columbia 
Aging Project provides the first evidence of a beneficial effect of the  Mediterranean diet 
on the risk of AD. However, the exact magnitude of such risk factors is still unknown. 
Histopathologically, the typical hallmarks of the disease include deposition of amyloid 
beta (Aβ) peptide in so-called senile plaques and accumulation of tau protein in cells, 
leading to neurofibrillary tangles and pyramidal cell loss.
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Cholinergic hypothesis  
and current treatments
In the past few decades, treatment for AD has largely 
involved replacement of neurotransmitters known to be 
lacking in AD, mostly based on the “cholinergic hypoth-
esis” of AD.1–3 This hypothesis states that a deficit in central 
cholinergic transmission caused by degeneration of the basal 
forebrain nuclei is an important pathologic and neurochemi-
cal feature of AD. A progressive loss of nicotinic receptors 
over the course of the disease has also been described,4 and 
there is evidence of a role for these receptors in memory and 
cognition deficits.5
Different strategies have been investigated to improve 
cholinergic neurotransmission, including increasing acetyl-
choline synthesis, augmentation of presynaptic acetylcholine 
release, stimulation of cholinergic postsynaptic muscarinic 
and nicotinic receptors, and reduction of acetylcholine syn-
aptic degradation with cholinesterase inhibitors. The current 
data do not support the use of precursors of acetylcholine, 
presynaptic releasing agents, or muscarinic agonists because 
of a lack of efficacy and unacceptable side effects.6
Acetylcholinesterase inhibitors act by restricting the 
ability of the cholinesterase enzyme to break down acetyl-
choline, thus increasing the concentration and duration of 
acetylcholine at sites of neurotransmission. So far, three 
acetylcholinesterase inhibitors are approved for the treatment 
of patients with mild-to-moderately severe AD, ie, donepezil, 
rivastigmine, and galantamine.
Donepezil is a reversible, specific acetylcholinesterase 
inhibitor. It is easily absorbed by the body and can be taken 
once a day, initially at 5 mg and then, after 4 weeks of use, 
titrated up to 10 mg per day. It was approved for the treat-
ment of mild-to-moderate AD in 1996.
Acetylcholinesterase inhibitors are associated with a 
range of side effects as a result of cholinergic stimulation in 
different areas of the brain and the periphery. Possible side 
effects include nausea, vomiting, diarrhea, and sleep distur-
bances, associated with cholinergic activity in the cortex, 
caudate nucleus, brainstem, and medulla, respectively, and 
muscle cramps, weakness, bradycardia (particularly in people 
with sick sinus syndrome or other supraventricular cardiac 
conduction conditions), and urinary incontinence, associated 
with peripheral cholinergic activity.7
There is evidence that donepezil is effective in improv-
ing and maintaining global outcomes in the short to medium 
term (12–24 weeks),8 and is supported by a large open-label 
trial that investigated the efficacy of donepezil in a routine 
setting in clinical practice.9 A meta-analysis showed that 
improvements in Mini-Mental State Examination score 
are maintained at 52 weeks with donepezil 10 mg/day 
compared with placebo.10 In the AD2000, a clinical trial of 
565 community residents, improvements in Mini-Mental 
State Examination score were maintained beyond 52 weeks 
with donepezil 5 or 10 mg/day.11 However, despite the effects 
of donepezil on major symptoms of AD, its impact on patient 
quality of life has not been consistently demonstrated, perhaps 
reflecting the difficulty of assessing this aspect in the AD 
patient population.8
Rivastigmine tartrate is an acetylcholinesterase inhibitor 
and also a butyrylcholinesterase inhibitor. Owing to its short 
half-life (1.5 hours), it has to be taken twice a day. Doses 
start at 3 mg per day and increase gradually to between 6 mg 
and 12 mg per day. Rivastigmine can be taken orally or by 
a transdermal patch, with doses of either 4.6 mg or 9.5 mg 
per 24 hours. Care should be exercised in patients with renal 
disease (due to its elimination pattern), mild or moderate liver 
disease (mainly metabolized by the liver), sick sinus syn-
drome, conduction abnormalities, gastric or duodenal ulcers, 
or a history of asthma or obstructive pulmonary disease. The 
main side effects are nausea and vomiting. However, these 
events can be minimized using slow dose escalation, with 
small dose graduations and administration with food.7
A Cochrane review by Birks et al considering nine trials 
with a total of 4,775 participants concluded that rivastigmine 
gives benefit to people with mild-to-moderate AD when com-
pared with placebo at 26 weeks.12 Indeed, the rivastigmine 
9.6 mg transdermal patch demonstrates the same efficacy but 
fewer side effects than capsules. The main adverse effects 
are gastrointestinal (nausea and vomiting), usually occurring 
during the titration phase.12
Rivastigmine preferentially inhibits the G1 isoform 
of cholinesterase, which is predominantly located in the 
cortex, hippocampus, and neuritic plaques, while donepezil 
and galantamine are not selective for any cholinesterase 
isoforms and have wide cholinergic activity both centrally 
and peripherally. The cholinergic activity of rivastigmine, in 
contrast with donepezil and galantamine, is apparently more 
targeted at clinically relevant brain sites.7
Two head-to-head studies comparing donepezil with 
high-dose and low-dose rivastigmine showed that results 
for rivastigmine on functional and global outcomes were 
significantly better than those for donepezil.13,14 Bullock 
conducted another head-to-head study comparing donepezil 
with rivastigmine, and found a similar decline in cognitive, 
behavioral, and functional domains in the two groups of 
patients at 2 years of follow-up.15
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Galantamine was originally made from snowdrop and 
narcissus bulbs, but is now produced synthetically. It is a 
reversible acetylcholinesterase inhibitor with a half-life of 
about 7 hours, indicating that it should be taken twice a 
day at the recommended dose of 16–24 mg each time. An 
alternative version is taken once a day at doses of 8, 16, or 
24 mg. The side effects of galantamine are similar to those 
of the other acetylcholinesterase inhibitors, and are mainly 
gastrointestinal (abdominal pain, diarrhea, nausea, and 
vomiting), although bradycardia and dizziness have been 
also reported.
Several randomized controlled trials (RCTs) have com-
pared the clinical efficacy of galantamine versus placebo. 
The benefit appears to vary depending on the dose, with 
greater benefits on cognition found with 16 and 32 mg/day 
after 21–26 weeks of treatment.16 With regard to functional 
ability, a number of RCTs have analyzed the effective-
ness of  galantamine versus placebo; the outcome measures 
considered were the Alzheimer’s Disease Cooperative 
Study-Activities of Daily Living inventory and the Disabil-
ity Assessment of Dementia scale. All studies found that 
participants receiving galantamine (16 mg/day, 24 mg/day, 
and/or 32 mg/day) experienced a significantly smaller dete-
rioration on galantamine compared with placebo.16
Ancori-Israel et al compared the effects of galantamine 
16 mg with those of donepezil 10 mg on patients’ and care-
givers’ sleep patterns. Their study was suggestive of small 
benefits resulting from galantamine treatment; however, the 
results were not statistically significant.17
Memantine
Memantine is approved for the treatment of moderate-to-
severe AD, as measured by a Mini-Mental State Examina-
tion score #20. It is a voltage-dependent, moderate-affinity, 
noncompetitive N-methyl-aspartate receptor antagonist, and 
is taken orally twice a day. The starting dose is 10 mg/day 
and can be increased to a maximum daily dose of 20 mg/day. 
Caution should be used when prescribing memantine for 
people with renal failure or epilepsy; it is also contraindicated 
for people with severe renal impairment. Side effects may 
include dizziness, confusion, headache, and incontinence.
An RCT evaluating the efficacy of memantine mono-
therapy demonstrated a beneficial effect on cognition at 12 
weeks but not at 24–36 weeks.16 A recent meta-analysis18 
confirmed a small but significant benefit of memantine 
combination therapy on cognitive, global, and behavior 
measures, but not on function/activities of daily living. In 
2012, a post-marketing surveillance study demonstrated that 
patients on a stable dosage of memantine are more likely to 
improve in affect, physical behavior, and psychosis domains 
than those on a modified dosage of memantine (defined as 
dose change or withdrawal during the study period). The size 
effect was modest, with behavioral improvement reported in 
only 24%–30% of patients.  Moreover, the study population 
might not have been representative of the AD population, 
because patients with clinical relevant comorbidity or taking 
other central nervous system drugs were excluded.19
In 2008, Qaseem et al20 developed a guideline to assist 
clinicians in the treatment decision, and made the following 
recommendations:
•	 clinicians should base the decision to initiate a trial of 
therapy with a cholinesterase inhibitor or memantine on 
individualized assessment (Grade: weak recommenda-
tion, moderate quality evidence)
•	 clinicians should base the choice of pharmacologic agent 
on tolerability, adverse effect profile, ease of use, and cost 
of medication; the evidence is insufficient to compare the 
effectiveness of different pharmacologic agents for the 
treatment of dementia (Grade: weak recommendation, 
low quality evidence)
•	 there is an urgent need for further research on the 
clinical effectiveness of pharmacologic management of 
dementia.
Cholinergic drugs under  
development or in clinical trials
Latrepirdine
Latrepirdine is an oral compound previously approved in 
 Russia as a nonselective antihistamine but was  withdrawn 
from the market after the development of more  selective drugs. 
In two studies, there was improvement over 6 months in all 
endpoints (cognitive, global, daily  functional  behavior), with 
continuing improvement in cognition and daily function at 
12 months. However, in the Phase III trial  (CONNECTION), 
latrepirdine failed on primary and  secondary endpoints.21 Two 
other Phase III studies  (CONTACT and  COSTELLATION) 
are in progress.22
Huperzine A
Huperzine A is a potent, selective, and well tolerated ace-
tylcholinesterase inhibitor, and is a Lycopodium alkaloid 
isolated from the Chinese folk medicine Huperzia serrata 
(Qian Ceng Ta). In multiple studies, it has shown a ben-
eficial effect on memory impairment in AβPP/PS1 mice 
after 8 weeks of administration. Unfortunately, in a recent 
Phase II trial, huperzine A 200 µg twice daily had no effect 
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on cognitive function in patients with mild to moderate 
AD.23 A Phase III clinical trial evaluating safety and efficacy 
of sustained-release huperzine A tablets versus placebo in 
patients with mild-to-moderate AD is ongoing.
Phenserine
Phenserine is a noncompetitive acetylcholinesterase 
inhibitor that has independent modulatory effects on Aβ 
generation. A recent study showed a statistically significant 
benefit on cognition from phenserine 15 mg versus placebo 
at 12 weeks.24
Ladostigil
Ladostigil (TV-3326) is a dual acetylcholine-butyrylcholin-
esterase and brain-selective monoamine oxidase A and B 
inhibitor in vivo, and intended for the treatment of dementia 
comorbid with extrapyramidal disorders and depression. 
Presently in a Phase IIb clinical study, ladostigil has been 
previously demonstrated to possess potent antiapoptotic and 
neuroprotective activity in vitro and in various neurodegen-
erative rat models.25
Amyloid hypothesis
According to the amyloid hypothesis, the deposition of Aβ 
is a central event in the etiology of AD.26 Aβ derives from 
the amyloid precursor protein, which can be processed by 
two different enzymes, ie, α-secretase and β-secretase.27 In 
both cases, the C-terminal fragment undergoes a subsequent 
additional cleavage event by an enzyme complex called 
γ-secretase. This second cleavage results in amyloid precur-
sor protein intracellular domain and either the p3 protein in 
the case of the α-secretase pathway or the Aβ in the case of 
the β-secretase pathway. Thus, the beta amyloid hypothesis 
suggests that beta amyloid deposition leads to tau pathology, 
as well as additional pathogenic mechanisms, such as inflam-
mation and oxidative damage, that result in cell death. Recent 
evidence suggests that the neurotoxic form of amyloid is 
soluble oligomers rather than monomers or the fibrillary form 
found in plaques.28 New therapeutic strategies aim to interfere 
with amyloid deposition, either influencing its formation or 
trying to remove it once deposited in senile plaques, and 
include mainly vaccination and passive immunization.
β-secretase and γ-secretase 
inhibitors
β-secretase 1 is an aspartyl protease that shares some 
features with human immunodeficiency aspartyl proteases. 
No known mutations in the gene encoding β-secretase have 
been related to familial AD. Because β-secretase 1 also has 
other substrates (including neuregulin-1, which is involved 
in myelination), development of inhibitors may theoretically 
face problems of toxicity related to nonspecific effects and 
blood-brain barrier penetration.24 The thiazolidinediones, 
rosiglitazone and pioglitazone, have been tested for AD in 
RCTs, and may in part act as suppressors of β-secretase 
expression. Rosiglitazone was shown to improve spatial 
learning and memory ability, and slightly decreased Aβ42 
(but not Aβ40) concentrations in the brain, without affecting 
the amyloid plaque burden in Tg2576 mice. In a Phase II 
study, after 6 months of treatment with rosiglitazone, patients 
with mild AD or amnestic mild cognitive impairment showed 
better delayed recall and selective attention as compared 
with a placebo group.29 A subsequent larger Phase III study 
showed no significant clinical benefit of rosiglitazone, ie, not 
confirming the preliminary observation made in the Phase II 
study.30 MK-8931 is a potent β-secretase 1 inhibitor, and has 
been shown to reduce Aβ levels in the cerebrospinal fluid and 
brains of rodents and primates. In Phase I trials, MK-8931 
has been generally safe and well tolerated. Two large double-
blind, placebo-controlled, Phase II/III RCTs are ongoing in 
patients with mild-to-moderate AD and prodromal AD.31,32
γ-secretase is a protease complex that cleaves proteins at 
residues within their single membrane spanning domain. The 
best known substrate of γ-secretase is amyloid precursor pro-
tein, cleavage of which produces Aβ. The γ-secretase complex 
consists of four individual proteins, ie, presenilin, nicastrin, 
APH-1, and PEN-2.33 Development of γ-secretase inhibitors 
as disease-modifying drugs presents problems related to their 
potential nonspecific effects. This is because γ-secretase is 
not only responsible for Aβ generation but is also involved 
in intramembranous cleavage of several proteins (ie, Notch 
receptor, ErbB4, p75 NTR neurotrophin receptor, N-cadherin, 
and the sodium channel β4 subunit).34
Semagacestat was the first γ-secretase inhibitor to undergo 
extensive clinical testing and was shown to reduce Aβ concen-
trations in plasma and Aβ production in the central nervous 
system.35 Two large Phase III studies with semagacestat were 
prematurely stopped because of serious collateral adverse 
effects, including hematologic, gastrointestinal, and skin 
toxicity, that have been attributed to inhibition of the Notch 
signaling pathway. Further, in these studies, no improvement 
or moderate worsening of cognition was observed, perhaps 
related to γ-secretase inhibition within the central nervous 
system.36
Notch-sparing γ-secretase inhibitors and/or modulators 
(agents that shift γ-secretase cleavage activity from longer 
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to shorter Aβ species without affecting Notch cleavage) are 
in clinical development. Begacestat, BMS-708163 (ava-
gacestat), and CHF-5074 display 10–100-fold selectivity for 
amyloid precursor protein over Notch cleavage. Begacestat 
showed significant reduction in plasma and cerebrospinal 
fluid levels of Aβ in animal models and a good safety and 
tolerability profile in Phase I studies. In a Phase I trial, 
doses of avagacestat .50 mg/day reduced cerebrospinal 
fluid concentrations of Aβ1–38, Aβ1–40, and Aβ1–42  in 
a dose-dependent fashion over 28 days of daily dosing 
without any sign of potential Notch-related dose-limiting 
toxicity.37 CHF-5074 showed a good safety and tolerability 
profile in Phase I clinical trials. Phase II trials are ongoing 
in patients with mild cognitive impairment (http://www.
clinicaltrial.gov).
Vaccination
The concept of immunotherapy for neurodegenerative dis-
eases was introduced by Schenk et al in 1999 when they used 
an Aβ vaccine to tackle AD.38 Their vaccine was composed 
of Aβ itself and the immunologic adjuvant QS21. In mice, 
it was extremely effective in reducing cerebral Aβ load and 
ameliorating cognitive performance. In 2001, a multicenter, 
randomized, placebo-controlled, double-blind, Phase II 
clinical trial using active immunization with Aβ42 plus an 
adjuvant was started in 300 patients. Unlike in the preclinical 
phase, severe adverse events occurred, consisting of aseptic 
meningoencephalitis in 18 treated patients. Therefore, the 
trial was halted after 2–3 injections. The final results of the 
trial were published in 2005.39
Double-blind assessment was maintained for 12 months, 
demonstrating no signif icant differences in cognition 
between antibody responders and a placebo group on 
neuropsychologic assessment. In 2008, a paper was pub-
lished describing the relationship between Aβ42 immune 
response, degree of plaque removal, and long-term clinical 
outcomes.40 In June 2003, 80 patients (or their caregivers), 
who had entered Phase I and II of the AN1792 trial, gave 
their consent for long-term clinical follow-up (maximum 
6 years) and post mortem neuropathologic examination. At 
autopsy, the mean Aβ load was lower in brains from patients 
who had received immunization than in the placebo cohort. 
However, despite this observation, no evidence of improved 
survival or improvement in time to develop severe dementia 
was observed in these patients. These results suggest that 
plaque removal is not enough to halt progressive neuronal 
death, prompting some intriguing challenges to the amyloid 
hypothesis.
Although severe adverse events occurred in the first 
AN1792 trial and cognitive results were unclear, immuniza-
tion was not abandoned. The first second-generation vaccine 
tested in patients with AD was CAD106 (Novartis, Basel, 
Switzerland), a vaccine that presents multiple copies of 
Aβ1–6 peptide derived from the N-terminal B cell epitope of 
Aβ, and avoids T cell activation. Administration of CAD106 
to APP transgenic mice showed a reduction of Aβ deposition 
in the brain. A double-blind, placebo-controlled, 52-week, 
Phase I study was carried out in two centers in Sweden,41 
and no cases of clinical or subclinical cases of meningoen-
cephalitis occurred.
Additional vaccines under clinical testing include: ACI-24 
(AC Immune, Lausanne, Switzerland), an Aβ1–15 peptide 
to which two lysines are attached on both ends, embedded 
in a liposome membrane; Affitope® AD02 (AFFiRiS AG, 
Vienna, Austria, and licensee GlaxoSmithKline Biologicals 
SA, Rixensart, Belgium), a six-amino acid peptide vaccine 
targeting the N-terminus of amyloid-β; Affitope AD03 
(AFFiRiS AG and licensee GlaxoSmithKline Biologicals); 
ACC-001 (vanutide cridificar; Pfizer Inc, Groton, CT, 
USA); UB-311 (United Biomedical Inc, Hauppauge, NY, 
USA); and V-950 (Merck and Co, Inc, Whitehouse Station, 
NJ, USA).42
Passive immunization
An alternate solution to avoid undesirable T cell-induced 
inflammation that can be a source of side effects is to use 
passive immunization with humanized antibodies. The 
first antibody tested in a Phase II trial was the human-
ized monoclonal anti-Aβ antibody bapineuzumab (Wyeth, 
Madison, NJ, USA, and Élan Corporation, Dublin, Ireland). 
This 18-month, multidose, one-to-one randomized trial was 
designed to assess safety, tolerability, and standard efficacy 
endpoints (ADAS-Cog) of multiple ascending doses of bap-
ineuzumab in patients. On May 2007, Élan Corporation and 
Wyeth announced their plans to start a Phase III clinical trial 
of bapineuzumab, based on all the clinical data accumulated 
from the Phase I and Phase II trials.43
Among the analyses carried out, different effects were 
observed when stratifying patients according to their apo-
lipoprotein E (ApoE) status. It seemed that ApoE noncar-
riers who received the second to lowest of the four doses 
six times responded better than the carriers. Therefore, two 
Phase III studies were started in ApoE4 noncarriers and car-
riers with mild-to-moderate AD (http://clinicaltrials.gov). 
Two multicenter, randomized, double-blind, placebo-con-
trolled Phase III studies reached completion in April and 
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June 2012. The first study compared 0.5 mg/kg and 1 mg/kg 
of bapineuzumab versus placebo. The second compared 
responses to bapineuzumab 0.5 mg/kg versus placebo in 
ApoEε4 carriers. Coprimary endpoints for each trial were the 
changes in ADAS-Cog and Disability Assessment of Demen-
tia scores from baseline. Secondary endpoints included 
brain amyloid burden on Pittsburgh compound B-positron 
emission tomography, cerebrospinal fluid, phospho tau, and 
brain volume on magnetic resonance imaging. In July 2012, 
Pfizer (having acquired Wyeth in 2009) reported that the 
study in ApoE4 carriers did not meet its primary endpoints 
and announced the discontinuation of the Phase III trials. 
However, a secondary endpoint analysis revealed a reduc-
tion in amyloid plaques on positron emission tomographic 
imaging in APOE 4 carriers with mild AD.44
Solanezumab (LY2062430; Eli Lilly, Indianapolis, IN, 
USA) is a humanized monoclonal antibody that binds to 
the central region of β-amyloid. A randomized, double-
blind, placebo-controlled, Phase II clinical trial was carried 
out to assess the safety, tolerability, pharmacokinetics, and 
pharmacodynamics of 12 weekly infusions of solanezumab 
in patients with mild-to-moderate AD. Clinical laboratory 
values, cerebrospinal fluid cell counts, and magnetic reso-
nance imaging scans were unchanged by treatment, and no 
adverse events could be clearly related to administration of 
the antibody. Two large Phase III trials (EXPEDITION1 and 
EXPEDITION2) are ongoing, showing that the treatment is 
effective in mild but not severe AD.44
Gantenerumab (R1450; Hoffman-LaRoche, Basel, 
Switzerland) has been optimized in vitro for binding with 
subnanomolar affinity to a conformational epitope expressed 
on Aβ fibrils using HuCAL® phage display technology. In 
peptide maps, both the N-terminal and central portions of 
Aβ were recognized by gantenerumab. A large Phase III 
clinical trial is ongoing.
Passive immunization is considered safer than active 
immunization, and no cases of encephalitis have been 
reported thus far. However, passive immunotherapy has 
its own side effects, most notably microhemorrhages and 
vasogenic edema. All these antibodies are built on the same 
immunoglobulin (IgG1) backbone, which is thought to 
activate microglia. Different from the previously described 
antibodies, crenezumab (MABT5102A; Genentech Inc, 
South San Francisco, CA, USA) possesses an IgG4 back-
bone, which has a milder effect on microglia because it binds 
more weakly to cell surface immunoglobulin receptors. 
Nonetheless, it is able to bind all forms of Aβ, including 
toxic oligomers. The first Alzheimer’s Prevention Initiative 
will study crenezumab in 300 people from a large family 
in Columbia with a rare genetic mutation that typically 
triggers AD symptoms around the age of 45 years, and is 
a collaboration between the National Institutes of Health, 
Banner’s Alzheimer’s Institute, and Genentech Inc.
Moreover, another large Phase II/III trial is ongoing to 
assess the safety, tolerability, and biomarker efficacy of gan-
tenerumab and solanezumab in individuals with autosomal 
dominant Alzheimer’s disease mutation. Additional anti-
bodies are in clinical development, including PF-04360365 
(Pfizer), GSK933776A (GlaxoSmithKline), NI-101 (Biogen 
Idec, Weston, MA, USA), PF-05236812 (Janssen Alzheimer 
Immunotherapy, South San Francisco, CA, USA, and Pfizer), 
RN6G (Pfizer), SAR-228810 (Sanofi SA, Paris, France), and 
BAN-2401 (Eisai Co, Ltd, Tokyo, Japan).44
Anti tau strategies
Tau is a cytoplasmic protein that binds to tubulin during 
its polymerization, thereby stabilizing microtubules. Tau is 
abnormally phosphorylated in AD, resulting in generation 
of aggregates (neurofibrillary tangles) toxic to neurons. 
Tau hyperphosphorylation can be promoted by imbalanced 
activity of protein kinase. One therapeutic approach is 
based on inhibitors of tau-phosphorylating kinase (glycogen 
synthase kinase-3 and p70-S6-kinase). Both lithium and 
valproate inhibit glycogen synthase kinase-3. A Phase III 
clinical trial demonstrated that treatment with valproate does 
not delay emergence of agitation or psychosis or slow cogni-
tive or functional decline in patients with moderate AD.45 In 
a recent RCT of 45 patients with amnestic mild cognitive 
impairment, treatment with lithium was associated with 
a significant decrease in concentrations of phospho tau in 
cerebrospinal fluid and better performance on the cognitive 
subscale of the ADAS-Cog and on attention tasks.46
Several glycogen synthase kinase-3 inhibitors are under 
development. NP-031112 (NP-12) is a thiazolidinedione-
derived compound that is able to induce neuroprotection and 
attenuate the production of proinflammatory cytokines and 
activation of astrocytes and microglial cells in a rat model of 
excitotoxicity.47 This compound has been tested in patients 
with Alzheimer’s disease in a Phase II RCT, but there are no 
definitive results.48
Another approach is based on compounds that inhibit 
tau aggregation and/or promote aggregate disassembly. 
Methylthioninium chloride, a reducing agent better known 
as methylene blue, interferes with tau aggregation by acting 
on self-aggregating truncated tau fragments.48 In a placebo-
controlled Phase II trial, methylthioninium chloride at 60 mg 
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was effective in slowing the rate of AD progression by 80% 
compared with placebo. An open-label Phase II study of 
methylthioninium chloride 30 mg and 60 mg is ongoing. 
A new formulation (leuco-methylthioninium), with better 
bioavailability and tolerability, was designed some years 
ago, and Phase III RCTs were planned to confirm its safety 
and clinical efficacy.48
Davunetide, an intranasally administered, eight-amino acid 
peptide fragment, is able to inhibit tau hyperphosphorylation. 
A Phase II RCT in patients with amnestic mild cognitive 
impairment demonstrated that it is safe, well tolerated, and 
has positive effects on cognition.49
Nicotinamide is the biologically active form of niacin 
(vitamin B3), and the precursor of coenzyme NAD+. In 
mouse models of AD, this compound is able to reduce brain 
concentrations of a species of phosphorylated tau (Thr231) 
that inhibits microtubule polymerization.50 A Phase II study 
in patients with mild-to-moderate AD has just ended, but no 
results are available as yet.
Finally, two studies of particular interest are ongoing. 
The first is a randomized, double-blind, placebo-controlled, 
parallel-group, 15-month Phase III trial of TRx0237 (TauRx 
Therapeutics Ltd, Aberdeen, Scotland) in subjects with 
mild to moderate AD. The second is a Phase I study with 
BMS-241027 (Bristol-Myers Squibb, New York City, NY, 
USA), evaluating the safety and pharmacodynamic effects 
of the drug on tau in cerebrospinal fluid, using functional 
connectivity magnetic resonance imaging and computerized 
cognitive tests in subjects with mild AD, following nine 
weekly intravenous infusions of BMS-241027.
Conclusion
Pharmacologic treatment of AD involves acetylcholin-
esterase inhibitors and memantine, which provide mainly 
symptomatic short-term benefits without counteracting 
the progression of the disease. In the last decade, despite a 
number of promising disease-modifying compounds having 
been developed, none has ever succeeded in Phase III trials. 
Therefore, additional mechanisms at the basis of AD patho-
genesis must be better understood; the amyloid hypothesis 
can explain part of the pathologic processes underlying AD, 
but Phase III studies of active or passive immunization have 
failed to demonstrate a cognitive benefit compared with 
placebo. This suggests that removing senile plaques is neces-
sary, but not sufficient to halt disease progression. Therefore 
it is of crucial importance to better understand the relationship 
between tau, Aβ, and other factors when developing novel 
potentially disease-modifying drugs.
Indeed, all past clinical trials were conducted in patients 
with mild-to-moderate AD. Disease-modifying drugs might 
work better in the preclinical stages of the disease, when Aβ 
and tau burden are not so compromising and patients are still 
autonomous in daily living tasks. That is why current and 
future trials will be designed to include patients in the pre-
clinical phase of the disease (prodromal AD), underscoring 
the need to identify tools for early diagnosis (ie, cerebrospinal 
fluid or radiologic biomarkers). Last, indicators useful as 
surrogate biomarkers should be identified in order to: have 
substitutes for clinical endpoints (at present, represented 
mainly by neuropsychologic testing); develop tools that are 
able to predict clinical benefit, or the opposite; and demon-
strate whether there are disease-modifying properties.
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